UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August, 2026.
Commission
File Number: 000-51848
Avricore
Health Inc.
(Exact
name of registrant as specified in its charter)
1120-789
West Pender St, Vancouver, BC, V6C 1H2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): NO
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report
to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): NO
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that
the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on EDGAR.
Exhibits
The
following exhibits are included in this form 6-K:
| Exhibit
No. |
|
Description |
|
Date
Released |
| 1 |
|
News Release - HealthTab™ Enters Multi-Year Collaboration Agreement with Abbott for Point-of-Care Testing Across the UK |
|
August
20, 2026 |
| 2 |
|
Material change report |
|
August
20, 2026 |
| 3 |
|
News Release - Avricore Grants Options |
|
August
28, 2026 |
| 4 |
|
Interim financial statements/report |
|
August
31, 2026 |
| 5 |
|
Interim MD&A |
|
August
31, 2026 |
| 99.6 |
|
52-109FV2 - Certification of interim filings - CFO |
|
August
31, 2026 |
| 7 |
|
52-109FV2 - Certification of interim filings - CEO |
|
August
31, 2026 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
AVRICORE
HEALTH INC. |
| |
|
|
| Date:
September 16, 2026 |
By |
/s/
Kiki Smith |
| |
|
Kiki
Smith |
| |
|
Chief
Financial Officer |
| SEC1815(04-09) |
Persons
who are to respond to the collection of information contained in this form are not required to respond unless the form displays a
currently valid OMB control number |
Exhibit 99.6
Form
52-109FV2
Certification
of Interim Filings
Venture
Issuer Basic Certificate
I,
Kiki Smith, CFO of Avricore Health Inc., certify the following:
| 1. | Review:
I have reviewed the interim financial report and interim MD&A (together, the “interim
filings”) of Avricore Health Inc. (the “issuer”) for the
interim period ended June 30, 2026. |
| 2. | No
misrepresentations: Based on my knowledge, having exercised reasonable diligence,
the interim filings do not contain any untrue statement of a material fact or omit to state
a material fact required to be stated or that is necessary to make a statement not misleading
in light of the circumstances under which it was made, with respect to the period covered
by the interim filings. |
| 3. | Fair
presentation: Based on my knowledge, having exercised reasonable diligence, the interim
financial report together with the other financial information included in the interim filings
fairly present in all material respects the financial condition, financial performance and
cash flows of the issuer, as of the date of and for the periods presented in the interim
filings. |
Date:
August 31, 2026
| /s/ Kiki
Smith |
|
| Kiki Smith,
CFO |
|
NOTE
TO READER
In
contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers’
Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment
and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in
NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment
and maintenance of
| i) | controls
and other procedures designed to provide reasonable assurance that information required to
be disclosed by the issuer in its annual filings, interim filings or other reports filed
or submitted under securities legislation is recorded, processed, summarized and reported
within the time periods specified in securities legislation; and |
| ii) | a
process to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with the
issuer’s GAAP. |
The
issuer’s certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge
to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability
of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52-109
may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports
provided under securities legislation.
